Clinical trialNCT06751238RecruitingPhase 1Interventional

Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).

SponsorNovartis PharmaceuticalsEnrollment20Juvenile Psoriatic Arthritis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Loma Linda University Health
Loma Linda, California, United States
Wendy De La Pena
Recruiting
University of Florida
Gainesville, Florida, United States
Christian Oliveros
Recruiting
Ann and Robert H Lurie Childs Hosp
Chicago, Illinois, United States
Pooja Patel
Recruiting
Col Uni Med Center New York Presby
New York, New York, United States
Lisa Imundo
Recruiting
Levine Childrens Hospital
Charlotte, North Carolina, United States
Sheetal Vora
Recruiting
Cincinnati Childrens Hospital
Cincinnati, Ohio, United States
Hermine Brunner
Recruiting
Univ Hosp Cleveland Medical Center
Cleveland, Ohio, United States
Ezequiel Borgia
Recruiting
Legacy Emanuel Research Hosp Portland
Portland, Oregon, United States
Daniel Joseph Kingsbury
Recruiting
Childrens Hosp Pittsburgh Upmc
Pittsburgh, Pennsylvania, United States
Margalit Rosenkranz
Recruiting
Texas Arthritis Center
El Paso, Texas, United States
Sanjay Chabra
Recruiting
University of Utah
Salt Lake City, Utah, United States
Peter Chiraseveenuprapund
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Secukinumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Sept 2025
Primary completion: 31 Oct 2029
Completion: 11 Mar 2031
Last update posted: 21 Aug 2026
Registered enrollment: 20
Registry id: NCT06751238

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.